PT-141, also known as Bremelanotide, is a synthetic peptide derived from Melanotan II. Unlike Melanotan, which primarily affects skin pigmentation, PT-141 targets melanocortin receptors (MC3R and MC4R) in the central nervous system. This activity influences sexual arousal pathways, making PT-141 unique as a peptide studied for sexual dysfunction. It is FDA-approved under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Other applications remain experimental.
How The Peptide Is Used in Research Settings
- Studied for treating sexual dysfunction in both men and women.
- Explored for its ability to improve libido and arousal independent of hormonal pathways.
- Investigated in metabolic and appetite research due to melanocortin receptor involvement.
- Examined as a possible adjunct in mood and stress-related studies.
Proposed Uses (Research Areas)
- Female sexual dysfunction research (FDA-approved for HSDD).
- Male erectile dysfunction and libido studies.
- Appetite and energy balance research models.
- Central nervous system and mood-related studies.
How It Is Dosed in Research Settings
- Injectable (Subcutaneous): FDA-approved dose is 1.75 mg given as needed, at least 45 minutes before anticipated sexual activity.
- Research dosing: Typically ranges from 0.5–2 mg per injection, not more than once within 24 hours, and no more than 8 doses per month.
- Handling: Supplied as prefilled autoinjectors or lyophilized powder; requires refrigeration and light protection.
Important Considerations
- Regulatory status: FDA-approved for HSDD in premenopausal women; all other uses remain experimental.
- Evidence base: Clinical trials confirm efficacy in improving sexual desire and satisfaction. Research continues in men and other populations.
- Safety: Reported side effects include nausea, flushing, headache, increased blood pressure, and injection site reactions. Not recommended for patients with uncontrolled hypertension or cardiovascular disease.
Disclaimer
This material is provided for educational purposes only and summarizes published research on PT-141 (Bremelanotide).
It is not medical advice. Except for its narrow FDA-approved indication, PT-141 is experimental and should not be viewed as a therapy for medical use.
This peptide is for research use only.